Riccardo Lencioni
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Riccardo Lencioni has a total of 414 co-authors. Here are the top co-authors by number of shared publications:
- Laura Crocetti
University of Pisa
9 shared publications - Masatoshi Kudo
Department of Gastroenterology and Hepatology Kindai University Faculty of Medicine Osaka Japan
5 shared publications Dania Cioni
3 shared publicationsJean-Francois H. Geschwind
Division of Interventional Radiology, Johns Hopkins University, Baltimore, USA
3 shared publicationsKeiko Nakajima
3 shared publicationsS. Nahum Goldberg
3 shared publications
Latest Publications
- Open Access
- 8 February 2023
- Published by MDPI AG in Diagnostics
- Vol. 13 (4) , 625
Imaging Diagnosis of Hepatocellular Carcinoma: A State-of-the-Art Review
Hepatocellular carcinoma (HCC) remains not only a cause of a considerable part of oncologic mortality, but also a diagnostic and therapeutic challenge for healthcare systems worldwide. Early detection of the disease and consequential adequate therapy are imperative to increase patients’ quality of life and survival. Imaging plays, therefore, a crucial role in the surveillance of patients at risk, the detection and diagnosis of HCC nodules, as well as in the follow-up post-treatment. The unique imaging characteristics of HCC lesions, deriving mainly from the assessment of their vascularity on contrast-enhanced computed tomography (CT), magnetic resonance (MR) or contrast-enhanced ultrasound (CEUS), allow for a more accurate, noninvasive diagnosis and staging. The role of imaging in the management of HCC has further expanded beyond the plain confirmation of a suspected diagnosis due to the introduction of ultrasound and hepatobiliary MRI contrast agents, which allow for the detection of hepatocarcinogenesis even at an early stage. Moreover, the recent technological advancements in artificial intelligence (AI) in radiology contribute an important tool for the diagnostic prediction, prognosis and evaluation of treatment response in the clinical course of the disease. This review presents current imaging modalities and their central role in the management of patients at risk and with HCC.
- 8 February 2023
- Published by MDPI AG in Diagnostics
- Vol. 13 (4) , 625
Open AccessImaging Diagnosis of Hepatocellular Carcinoma: A State-of-the-Art Review
Hepatocellular carcinoma (HCC) remains not only a cause of a considerable part of oncologic mortality, but also a diagnostic and therapeutic challenge for healthcare systems worldwide. Early detection of the disease and consequential adequate therapy are imperative to increase patients’ quality of life and survival. Imaging plays, therefore, a crucial role in the surveillance of patients at risk, the detection and diagnosis of HCC nodules, as well as in the follow-up post-treatment. The unique imaging characteristics of HCC lesions, deriving mainly from the assessment of their vascularity on contrast-enhanced computed tomography (CT), magnetic resonance (MR) or contrast-enhanced ultrasound (CEUS), allow for a more accurate, noninvasive diagnosis and staging. The role of imaging in the management of HCC has further expanded beyond the plain confirmation of a suspected diagnosis due to the introduction of ultrasound and hepatobiliary MRI contrast agents, which allow for the detection of hepatocarcinogenesis even at an early stage. Moreover, the recent technological advancements in artificial intelligence (AI) in radiology contribute an important tool for the diagnostic prediction, prognosis and evaluation of treatment response in the clinical course of the disease. This review presents current imaging modalities and their central role in the management of patients at risk and with HCC.
- 17 November 2016
- Published by Elsevier in Annals of Oncology
- Vol. 27, vii90
Global GIDEON data: Subgroup analysis of sorafenib dosing pattern in patients with unresectable hepatocellular carcinoma
Background: Sorafenib (SOR) is an oral multikinase inhibitor approved for the treatment of advanced hepatocellular carcinoma (HCC) with a recommended 800mg/d dose defined based on phase 1, 2 and 3 studies. With data from the GIDEON global, prospective, observational study conducted in HCC patients (pts) in 39 countries, this subgroup analysis evaluates dosing patterns, dose determining factors, and safety and efficacy by initial SOR dose.
- 17 November 2016
- Published by Elsevier in Annals of Oncology
- Vol. 27, vii90
Global GIDEON data: Subgroup analysis of sorafenib dosing pattern in patients with unresectable hepatocellular carcinoma
Background: Sorafenib (SOR) is an oral multikinase inhibitor approved for the treatment of advanced hepatocellular carcinoma (HCC) with a recommended 800mg/d dose defined based on phase 1, 2 and 3 studies. With data from the GIDEON global, prospective, observational study conducted in HCC patients (pts) in 39 countries, this subgroup analysis evaluates dosing patterns, dose determining factors, and safety and efficacy by initial SOR dose.
- 30 August 2016
- Published by Cambridge University Press (CUP)
- p. 85-90
Assessment and triage of hepatocellular carcinoma
- 30 August 2016
- Published by Cambridge University Press (CUP)
- p. 85-90
Assessment and triage of hepatocellular carcinoma
- 21 September 2015
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 39 (3) , 334-343
Treatment of Liver Tumors with Lipiodol TACE: Technical Recommendations from Experts Opinion
Transarterial chemoembolization with Lipiodol (Lipiodol TACE), also called conventional TACE, was developed in the early 1980s and widely adopted worldwide after randomized control trials and meta-analysis demonstrated superiority of Lipiodol TACE to best supportive care. Presently, there is no level one evidence that other TACE techniques are superior to Lipiodol TACE for intermediate stage hepatocellular carcinoma (HCC), which includes patients with preserved liver function and nonsurgical large or multinodular HCC without distant metastases. In addition, TACE is part of the treatment for progressive or symptomatic liver metastases from gastroenteropancreatic neuroendocrine tumors. When injected into the hepatic artery, Lipiodol has the unique property of selective uptake and retention in hyperarterialyzed liver tumors. Lipiodol/drug emulsion followed by particle embolization has been demonstrated to improve the pharmacokinetic of the drug and tumor response. Radio opacity of Lipiodol helps to monitor treatment delivery, with retention of Lipiodol serving as an imaging biomarker for tumor response. For 30 years, Lipiodol TACE has been inconsistently referenced in many publications with various levels of details for the method of preparation and administration, with reported progressive outcomes following improvements in the technique and the devices used to deliver the treatment and better patient selection. Consequently, there is no consensus on the standard method of TACE regarding the use of anticancer agents, embolic material, technical details, and the treatment schedule. In order to develop an internationally validated technical recommendation to standardize the Lipiodol TACE procedure, a worldwide panel of experts participated in a consensus meeting held on May 10, 2014 .
- 21 September 2015
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 39 (3) , 334-343
Treatment of Liver Tumors with Lipiodol TACE: Technical Recommendations from Experts Opinion
Transarterial chemoembolization with Lipiodol (Lipiodol TACE), also called conventional TACE, was developed in the early 1980s and widely adopted worldwide after randomized control trials and meta-analysis demonstrated superiority of Lipiodol TACE to best supportive care. Presently, there is no level one evidence that other TACE techniques are superior to Lipiodol TACE for intermediate stage hepatocellular carcinoma (HCC), which includes patients with preserved liver function and nonsurgical large or multinodular HCC without distant metastases. In addition, TACE is part of the treatment for progressive or symptomatic liver metastases from gastroenteropancreatic neuroendocrine tumors. When injected into the hepatic artery, Lipiodol has the unique property of selective uptake and retention in hyperarterialyzed liver tumors. Lipiodol/drug emulsion followed by particle embolization has been demonstrated to improve the pharmacokinetic of the drug and tumor response. Radio opacity of Lipiodol helps to monitor treatment delivery, with retention of Lipiodol serving as an imaging biomarker for tumor response. For 30 years, Lipiodol TACE has been inconsistently referenced in many publications with various levels of details for the method of preparation and administration, with reported progressive outcomes following improvements in the technique and the devices used to deliver the treatment and better patient selection. Consequently, there is no consensus on the standard method of TACE regarding the use of anticancer agents, embolic material, technical details, and the treatment schedule. In order to develop an internationally validated technical recommendation to standardize the Lipiodol TACE procedure, a worldwide panel of experts participated in a consensus meeting held on May 10, 2014 .
- 1 September 2015
- Published by Elsevier in Techniques in Vascular and Interventional Radiology
- Vol. 18 (3) , 135-139
Irreversible Electroporation in the Treatment of Hepatocellular Carcinoma
- 1 September 2015
- Published by Elsevier in Techniques in Vascular and Interventional Radiology
- Vol. 18 (3) , 135-139
Irreversible Electroporation in the Treatment of Hepatocellular Carcinoma
- 31 July 2015
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 39 (3) , 409-416
Imaging Features of Radiofrequency Ablation with Heat-Deployed Liposomal Doxorubicin in Hepatic Tumors
The imaging features of unresectable hepatic malignancies in patients who underwent radiofrequency ablation (RFA) in combination with lyso-thermosensitive liposomal doxorubicin (LTLD) were determined.
- 31 July 2015
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 39 (3) , 409-416
Imaging Features of Radiofrequency Ablation with Heat-Deployed Liposomal Doxorubicin in Hepatic Tumors
The imaging features of unresectable hepatic malignancies in patients who underwent radiofrequency ablation (RFA) in combination with lyso-thermosensitive liposomal doxorubicin (LTLD) were determined.
- 1 March 2014
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 25 (3) , 365-369
Transarterial Treatment of Colorectal Cancer Liver Metastases with Irinotecan-Loaded Drug-Eluting Beads: Technical Recommendations
- 1 March 2014
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 25 (3) , 365-369
Transarterial Treatment of Colorectal Cancer Liver Metastases with Irinotecan-Loaded Drug-Eluting Beads: Technical Recommendations
- Open Access
- 28 November 2013
- Published by Hindawi Limited in International Journal Of Clinical Practice
- Vol. 68 (5) , 609-617
GIDEON (Global Investigation of therapeutic DE cisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis
Background GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma [HCC] and Of its treatment with sorafeNib) is a global, prospective, non‐interventional study undertaken to evaluate the safety of sorafenib in patients with unresectable HCC in real‐life practice, including Child‐Pugh B patients who were excluded from clinical trials. Methods Patients with unresectable HCC, for whom the decision to treat with sorafenib, based on the approved label and prescribing guidelines, had been taken by their physician, were eligible for inclusion. Demographic data and disease/medical history were recorded at entry. Sorafenib dosing and adverse events (AEs) were collected at follow‐up visits. The second interim analysis was undertaken when ~1500 treated patients were followed up for ≥ 4 months. Results Of the 1571 patients evaluable for safety, 61% had Child‐Pugh A status and 23% Child‐Pugh B. The majority of patients (74%) received the approved 800 mg initial sorafenib dose, regardless of Child‐Pugh status; however, median duration of therapy was shorter in Child‐Pugh B patients. The majority of drug‐related AEs were grade 1 or 2, and the most commonly reported were consistent with previous reports. The incidence and nature of drug‐related AEs were broadly similar across Child‐Pugh, Barcelona Clinic Liver Cancer (BCLC) and initial dosing subgroups, and consistent with the overall population. Conclusions Consistent with the first interim analysis, overall safety profile and dosing strategy are similar across Child‐Pugh subgroups. Safety findings also appear comparable irrespective of initial sorafenib dose or BCLC stage. Final analyses in > 3000 patients are ongoing.
- 28 November 2013
- Published by Hindawi Limited in International Journal Of Clinical Practice
- Vol. 68 (5) , 609-617
Open AccessGIDEON (Global Investigation of therapeutic DE cisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis
Background GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma [HCC] and Of its treatment with sorafeNib) is a global, prospective, non‐interventional study undertaken to evaluate the safety of sorafenib in patients with unresectable HCC in real‐life practice, including Child‐Pugh B patients who were excluded from clinical trials. Methods Patients with unresectable HCC, for whom the decision to treat with sorafenib, based on the approved label and prescribing guidelines, had been taken by their physician, were eligible for inclusion. Demographic data and disease/medical history were recorded at entry. Sorafenib dosing and adverse events (AEs) were collected at follow‐up visits. The second interim analysis was undertaken when ~1500 treated patients were followed up for ≥ 4 months. Results Of the 1571 patients evaluable for safety, 61% had Child‐Pugh A status and 23% Child‐Pugh B. The majority of patients (74%) received the approved 800 mg initial sorafenib dose, regardless of Child‐Pugh status; however, median duration of therapy was shorter in Child‐Pugh B patients. The majority of drug‐related AEs were grade 1 or 2, and the most commonly reported were consistent with previous reports. The incidence and nature of drug‐related AEs were broadly similar across Child‐Pugh, Barcelona Clinic Liver Cancer (BCLC) and initial dosing subgroups, and consistent with the overall population. Conclusions Consistent with the first interim analysis, overall safety profile and dosing strategy are similar across Child‐Pugh subgroups. Safety findings also appear comparable irrespective of initial sorafenib dose or BCLC stage. Final analyses in > 3000 patients are ongoing.
- 11 July 2013
- Published by Springer Nature
- p. 339-343
Combination Therapies in the Treatment of Primary Liver Cancers
- 11 July 2013
- Published by Springer Nature
- p. 339-343
Combination Therapies in the Treatment of Primary Liver Cancers
- Open Access
- 14 March 2013
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 19 (6) , 1312-1314
New Data Supporting Modified RECIST (mRECIST) for Hepatocellular Carcinoma
The modified Response Evaluation Criteria in Solid Tumors (mRECIST) guideline has introduced specific amendments to standard RECIST to address the unique complexities involved in the evaluation of tumor response in hepatocellular carcinoma. A growing amount of data suggests that mRECIST, designed for response assessment in clinical trials, may translate into a tool for clinical practice. Clin Cancer Res; 19(6); 1312–4. ©2013 AACR.
- 14 March 2013
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 19 (6) , 1312-1314
Open AccessNew Data Supporting Modified RECIST (mRECIST) for Hepatocellular Carcinoma
The modified Response Evaluation Criteria in Solid Tumors (mRECIST) guideline has introduced specific amendments to standard RECIST to address the unique complexities involved in the evaluation of tumor response in hepatocellular carcinoma. A growing amount of data suggests that mRECIST, designed for response assessment in clinical trials, may translate into a tool for clinical practice. Clin Cancer Res; 19(6); 1312–4. ©2013 AACR.